Following its acquisition of Salix Pharmaceuticals in 2015, Valeant entered a new therapeutic area, gastrointestinal disorders.


The gastrointestinal (GI) segment is a growing specialty market with significant unmet needs, many of which are chronic, can be damaging to the quality of life and are often undertreated. Among Salix’s key products are Xifaxan® 550 mg (indicated for irritable bowel syndrome with diarrhea and hepatic encephalopathy), Xifaxan 200 mg (traveler’s diarrhea), Relistor® (opioid-induced constipation), and Uceris® and Apriso® (ulcerative colitis).

Other GI products include Ruconest®, Giazo®, Moviprep®, Osmoprep®, Solesta®, Fulyzaq®, Deflux®, Glumetza®, Cycloset® and Zegerid®.

With an expanded sales force and a greater focus on direct-to-consumer and patient engagement marketing, Valeant is committed to providing healthcare professionals and patients the most effective solutions in gastroenterology.